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SUMMARY
Septic shock is a complex event with activation of 
many inflammatory pathways. Recent advances have 
begun to make some sense of the pathophysiological 
events. This review describes the historical 
background to the contemporary concepts and 
outlines the important role that cytokines probably 
have in the pathophysiology of septic shock. A
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consequence of the changing understanding of septic 
shock is that new therapeutic interventions are 
becoming available.
INTRODUCnON
‘ Humanity has but three great enemies: fever, famine 
and war. Of these, by far the greatest, by far the most 
terrible, is fever’. Sir William Osier
This review will discuss the history of, and recent 
advances in, septic shock, an area which has seen 
major advances over the past few years which may 
soon lead to novel therapeutic measures.
In 1899 a young patient developed Gram-negative 
bacteraemia and died.1 This, probably the first 
reported case of Gram-negative septic shock2 had 
many of the features later recognised as typical of the 
syndrome. The condition was due to a Gram-negative 
organism, occurred in a hospitalised patient and 
proved fatal. Research into septic shock built upon 
interest in fever, infection and cardiovascular 
physiology.
Measurements of body temperature became 
available with the development of the calibrated, 
sealed mercury thermometer. By 1798 James 
Curries had suggested the use of the thermometer in 
clinical medicine4 and therm om etry becam e 
sufficiently established for David Livingstone to take 
a thermometer on his travels, noting his temperature 
rising to 103°F during ‘African fever.5 Non-invasive 
measurement of blood pressure became practicable 
with the development of the mercury-in-glass 
sphymomanometer.6 In spite of extensive clinical 
observation in fever and the interest in cardiovascular 
physiology, no relationship between infection and 
hypotension was noted until the end of the nineteenth 
century. Studies of Gram-negative infection in the 
p re-an tib io tic  era did not com m ent on the 
cardiovascular status of the patients although most of 
the features of what came to be known as ‘septic 
shock’ were noted.7
With the advent of antibiotics Gram-negative 
septicaemia and septic shock became more common, 
from 1951 to 1958 Gram-negative septicaemia 
increased from 0.75/1,000 hospital admissions to 
4/1,000 in a US teaching hospital.8 Waisbren9 
recognised three different syndromes amongst 
patients with Gram-negative septicaemia, some 
remained well, some were hot, dry and flushed,
normotensive, with bounding pulses, whilst others 
were cold, clammy, lethargic and hypotensive. These 
frequently confirmed presentations are now known 
as ‘warm shock’ and ‘cold shock’.
Recent studies ’ of the cardiovascular 
abnormalities in septic shock show then to be 
different from those found in shock produced by 
other means. Patients with septic shock fall into two 
groups, those with a hyperdynamic and those with a 
hypodynamic circulation. Differences in cardiac 
output are important, those presenting with a high 
cardiac output being more likely to survive. Low 
cardiac output is associated with acidosis, suggesting 
poor tissue perfusion.
The initial event following Gram-negative 
septicaemia is probably peripheral vasodialatation. 
During this phase the skin is warm and dry (warm 
shock). It is not clear whether warm shock and cold 
shock arc separate responses to an infection or the 
ends of a spectrum of possible responses. The 
transition from warm shock to cold shock may be due 
to the development of myocardial failure, the cardiac 
index falls as the heart can no longer compensate for
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the low peripheral resistance; the skin becomes
cold and clammy, hypotension and failure of organ
perfusion develops. Myocardial depression and the
presence of circulating myocardial depressant
substances have been demonstrated in experimental
animals, following injections of lipopolysaccharide
(LPS), and in man during septic shock. Areas of
abnormal m yocardial contraction have been
dem onstrated in the hearts of patients with 
• 12 13 14 septicaemia. ’ ’
Role of Lipopolysaccharide:The suggestion that 
organisms released a toxic substance was made 
following observations of serious illness, including 
shock and death, in patients even though organisms 
in their blood were known not to be viable.1 ’16 The 
toxic component of these bacterial was shown to be 
LPS. The lethal effect of dead bacterial had first been 
demonstrated in 1885 when dead typhoid bacilli 
were shown to cause fever and death. Welch 
suggested that microbial agents cause fever by 
causing releasing ‘ferments’, possibly from white 
cells, a remarkable prescient suggestion. Bacterial 
LPS was identified as a probable cause of septic 
shock since when given in travenously  to 
experimental animals they induce a syndrome similar 
to that seen with natural infection.18,19
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LPS consists of lipid A, core polysaccharide and 
‘0 ’ chain polysaccharides. The lipid A and core 
polysaccharides which are responsible for the toxic 
properties, are common to all Gram-negative 
organisms; the O chain polysaccharides confer the 
antigenic differences between LPS. LPS, an integral 
part of the cell wall is released into the surrounding 
medium when the bacterium disintegrates, 
therefore o rgan ism s may produce sim ilar 
pathophysiological changes. The terms endotoxin 
and lipopolysaccharide are frequently used 
interchangably.
The observation that antibodies against the LPS 
core have a protective effect against the severe effects 
of Gram-negative bacteraemia has lead to the 
developm ent of polyclonal and m onoclonal 
antibodies raised against the core part of LPS. These 
antibodies should theoretically be active against a 
wide range of Gram-negative organisms. Trials of 
polyclonal antisera, and more recently monoclonal 
antibody have shown a reduction in mortality21 in 
some documented Gram-negative infection and 
shock, although it is as yet unclear how useful these 
antibodies will be in the clinical situation. 
Mediators of L ipopolysaccharide Toxi- 
city:Cytokines: Recent work suggests thatLPS itself 
is not the cause of the events associated with it, but 
initiates the release of endogenous mediators. In 
mice a simple mutation can confer resistance to the 
effects of LPS, sensitivity can be restored by bone 
marrow ablation and reconstitution with cells from 
sensitive mice suggesting that sensitivity is 
conferred by marrow derived cells, sensitivity can 
also be reconstituted by the transfer of macrophages. 
Macrophages are known to take up LPS24 and are 
involved in the release of mediators which are 
effectors of LPS induced toxicity.
Interleukin-1 (IL-1) and tumour necrosis factor 
(TNF), polypeptide cytokines which are known to be 
pyrogens, arc released my macrophages after 
stimulation with LPS.22’ 25 Interleukin-1 was first 
describes as ‘endogenous pyrogen’. Beeson showed 
that peritoneal exudate cells released a fever 
producing substance that was not LPS. Later
* Of\ 77studies ’ showed that this substance could induce 
a fever in animals made tolerant to bacterial pyrogen, 
and that the property of fever induction in whole 
blood incubated with LPS resided in the white cells. 
Endogenous pyrogen has been shown to be the same
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substance as leucocytic endogenous mediator(LEM), 
a mediator, produced by white cells which initiates 
events of the acute phase response such as 
hypoferraemia.28 EP/LEM  is now known as 
Interleukin-1 and is known to be a macrophage 
product, IL-1 has been purified and cloned and 
comprises two different molecules IL-1 and IL-B 
which have similar physiological actions. IL-1 is now 
known to be synthesised by a wide variety if cells. 
The biological effects are widespread and similar to 
those described  to endogenous pyrogen. 
Recombinant IL-1 produces fever and stimulated 
prostaglandin synthesis. Many of the features of the 
acute phase response, synthesis of serum amyloid A, 
alpha-1 antitrypsin and neutrophilia are seen (see ref 
29 for review).
In the late nineteenth century, following an 
observation that some patients with spontaneous 
regression from advanced cancers had had 
concurrent bacterial infections, Dr William Coley 
began to treat some of his patients with killed 
preparations of Gram-negative bacterial. Some of the 
patients made dramatic improvements and in 1934 
the American Medical Association stated the Coley’s 
toxins were the only known systematic therapy for 
cancer. Serum from animals injected with LPS was 
shown to cause necrosis of tumours, this factor was 
further characterised and found to be a macrophage 
product. Meanwhile an endogenous cachexia 
producing factor (cachectin) had been identified in 
chronically infected rabbits. Subsequent purification, 
cloning and sequencing of TNF and cachectic 
showed that they are identical. TNF and IL-1 have
similar properties as mediators of the inflammatory 
31, 32,33response.
IL-1 and TNF are involved in many of the 
phenomena associated with inflammation, which 
occur following LPS injection. LPS induces 
production of both of these cytokines and, 
macrophage released cytokines are though to be 
important in the pathophysiology of Gram-negative 
sepsis.29,31 TNF is released by macrophages upon 
stimulation by LPS, it is toxic in normal animals and 
produces pathology similar to that seen following 
septic shock. Neutralisation of TNF is elevated in 
man during severe infection, extremely high levels 
being reported in mcningococcaemia, high levels 
being associated with poor outcome. A similar 
association has been shown in cerebral malaria.40
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Experimental animals infused with lethal numbers of 
Gram-negative organisms have high TNF levels.41 
The evidence is such that TNF has been called the 
mediator of septic shock. However TNF is unlikely 
to be the sole mediator involved. Evidence from germ 
free animals and on the synergistic interaction 
between cytokines, interferons and LPS suggest that 
other mediator are probably involved.35 IL-1 receptor 
blockage interferes with the effects of LPS, 
suggesting that TNF alone is not responsible for the
development of septic shock.36 IL-1 has also been
37 38shown to be hypotensive. ’
The interactions between the cytokines and LPS as 
well as interactions with other bacterial products such 
as Staphylococcal toxic shock syndrome toxin-1 
(TSST-1)43 are important in our understanding of 
clinical ‘septic shock’ Products of Gram-positive 
organisms arc known to stimulate TNF production 
and to sensitise animals to the effects of LPS.44 The 
demonstration of synergy between LPS and TNF 
suggests that hypotension may develop in the 
presence of levels of these substances which alone 
would not be toxic.
Leukotrienes, Prostaglandins and PAF: LPS
stimulates the release of a large number of vasoactive 
mediators which have a role to play in the 
pathogenesis of septic shock. Lipid-1 and the 
polysaccharide part of LPS activate complement by 
the classical and alternate pathways; C3a and C5b 
vasodialatory anaphylatoxins are released. Platelet 
activating factor (PAF) rises after LPS infusion and 
PAF antagonists prevent death in one model of 
endotovin shock. Products of arachidonic acid 
m etabolism  via both the cyclo -oxygenase 
(prostaglandins) and lipoxygenase (leucotricnes) 
pathways appear in septic shock 45 Phospholipase A2 
(PLA2) causes the release of arachidonic acid from 
membrane bound phosholipids; PLA2 is hypotensive 
in a rabbit model, PLA2 levels rise following 
injections of LPS and that there is a relationship 
between the levels of PLA2 and the fall in mean blood 
pressure. Pretreatment the animals with systemic 
glucocorticoids prevents the rise in PLA2 following 
LPS and hypotension. Glucocorticoids are known to 
induce an inhibitor of PLA2 activity (lipocortin).46
If TNF and IL-1 are proximal mediators of 
endotoxin shock they should activate these pathways 
which are believed to be involved in the pathogenesis 
of endotoxin shock, there is evidence that they do.
TNF induces eicosanoid synthesis, and increases 
PLA2 activity.47 The involvement of the cytokines in 
the synthesis of products of arachidonic acid 
metabolism may explain the action of non-steroidal 
anti inflammatory agents in blocking the action of 
11-1 and TNF.
The role of IL-1 and TNF in the normal response 
to infection is uncertain. There is evidence that fever 
is a beneficial adaptive response48 and that the other 
components of the acute phase response, such as 
hypofcrracmia confer some protection against 
infection. Whilst it is unknown that 11-1 and TNF are 
endogenous pyrogens and trigger the acute phase 
response raised levels of these cytokines have not 
demonstrated in patients with fever who are 
otherwise well.
The difference between the person who develops 
a fever and remains cardiovascularly normal and the 
person who develops septic shock i terms of their 
levels of LPS, IL-1 and TNF remains uncertain, 
although detectable of any of these arc associated 
with the development of shock. Prospective-studies 
of the levels of cytokines in patients at risk of 
developing septic shock, in conjunction with trials of 
anticytokine therapy have started.
CONCLUSION
The developing understanding of the roles of the 
cytokines, in particular TNF and IL-1 in the 
pathogenesis of septic shock helps to explain why a 
wide variety of stinuli can produce a similar final 
pathway. The complex response of interacting 
cytokines released following infection or exposure to 
bacterial products is a potential area for therapeutic 
intervention. Septic shock is a severe condition with 
high mortality and it is likely that antidotes to these 
mediators as well as anti-LPS antibodies will become 
important in the treatment of septic shock in the near 
future.
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